NCT03199872View on ClinicalTrials.gov

RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

August 1, 2018

Study Completion Date

March 29, 2019

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

RV001V

Sc injection

Trial Locations (1)

2400

Rigshospitalet, Copenhagen

All Listed Sponsors
collaborator

Dantrials Aps

INDUSTRY

lead

RhoVac APS

INDUSTRY

NCT03199872 - RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours | Biotech Hunter | Biotech Hunter